research use only

Memantine HCl NMDAR antagonist

Cat.No.S2043

Memantine HCl is an antagonist of NMDAR. It is also a CYP2B6 and CYP2D6 inhibitor for recombinant CYP2B6 and CYP2D6 with IC50 of 1.12 μM and 242.4 μM, Ki of 0.51 μM and 84.4 μM, respectively.
Memantine HCl NMDAR antagonist Chemical Structure

Chemical Structure

Molecular Weight: 215.76

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 215.76 Formula

C12H21N.HCl

Storage (From the date of receipt)
CAS No. 41100-52-1 Download SDF Storage of Stock Solutions

Synonyms N/A Smiles CC12CC3CC(C1)(CC(C3)(C2)N)C.Cl

Solubility

In vitro
Batch:

DMSO : 43 mg/mL ( (199.29 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : 43 mg/mL

Ethanol : 43 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
NMDAR [1]
CYP2B6 [2]
(Cell-free assay)
0.51 μM(Ki)
CYP2B6 [2]
(Cell-free assay)
1.12 μM
CYP2D6 [2]
(Cell-free assay)
84.4 μM(Ki)
CYP2D6 [1]
(Cell-free assay)
242.4 μM
In vitro

Memantine inhibits CYP2B6 and CYP2D6 activities with Ki of 76.7 and 94.9 µM, respectively, in human liver microsomes.

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06275035 Recruiting
Neurocognitive Dysfunction
Tata Memorial Centre
February 22 2024 Phase 3
NCT05804279 Completed
Healthy
Hyundai Pharm
December 28 2022 Phase 1
NCT05063851 Recruiting
Alzheimer Disease
University of Virginia
October 11 2021 Phase 2
NCT05015595 Unknown status
Obsessive-Compulsive Disorder
University of Roma La Sapienza
September 1 2021 Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.